The 44 references in paper O. Beresneva N., M. Parastaeva M., N. Shved V., G. Ivanova T., A. Kucher G., I. Kayukov G., A. Smirnov V., О. Береснева Н., М. Парастаева М., Н. Швед В., Г. Иванова Т., А. Кучер Г., И. Каюков Г., А. Смирнов В. (2015) “КОМБИНИРОВАННОЕ ВЛИЯНИЕ ВОЗРАСТА И СОКРАЩЕНИЯ МАССЫ ДЕЙСТВУЮЩИХ НЕФРОНОВ НА РЕМОДЕЛИРОВАНИЕ МИОКАРДА У КРЫС // THE COMBINED INFLUENCE OF AGE AND REDUCE THE WEIGHT OF EXISTING NEPHRONS ON MYOCARDIAL REMODELING IN RATS” / spz:neicon:nefr:y:2015:i:4:p:100-107

1
Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296-1305
(check this in PDF content)
2
Ninomiya T, Kiyohara Y, Kubo M et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68(1): 228-236
(check this in PDF content)
3
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15 [Smirnov AV, Dobronravov VA, Kajukov IG. Kardiorenal'nyj kontinuum: patogeneticheskie osnovy preventivnoj nefrologii. Nefrologija 2005; 9(3): 7-15]
(check this in PDF content)
4
Foley RN, Parfrey PS. Cardiac disease in chronic uremia: clinical autcome and risk factors. Adv Renal Replace Ther 1997; 4: 234-248
(check this in PDF content)
5
Jimbo R, Shimosawa T. Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease. Int J Hypertens 2014;
(check this in PDF content)
6
McCullough PA, Kellum JA, Haase M et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 82-98
(check this in PDF content)
7
North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012; 110(8): 1097-1108
(check this in PDF content)
8
Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011; 8:13–28;
(check this in PDF content)
9
Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933–944
(check this in PDF content)
10
Muller M, Smulders YM, de Leeuw PW, Stehouwer CD. Treatment of hypertension in the oldest old: a critical role for frailty? Hypertension 2014; 63(3): 433-441
(check this in PDF content)
11
Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part I: aging arteries: a «set up» for vascular disease. Circulation 2003; 107:139–146;
(check this in PDF content)
12
Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises, part II: the aging heart in health: links to heart disease. Circulation 2003; 107: 346–354
(check this in PDF content)
13
Pruthi R, Steenkamp R, Feest T. Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. Nephron Clin Pract 2013; 125(1-4): 139-169.
(check this in PDF content)
14
Amann K, Ritz E. Cardiovascular abnormalities in ageing and in uraemia-only analogy or shared pathomechanisms? Nephrol Dial Transplant 1998; 13 Suppl 7: 6-11
(check this in PDF content)
15
Ormrod D, Miller T. Experimental uremia description of a model producing varying degrees of stable uremia. Nephron 1980; 26: 249-254
(check this in PDF content)
16
Береснева ОН, Парастаева ММ, Иванова ГТ и др. Роль кетостерила в нефропротекции и кардиопротекции при экспериментальной уремии. Нефрология 2006; 10(1): 56-61 [Beresneva ON, Parastaeva MM, Ivanova GT i dr. Rol’ ketosterila v nefroprotekcii i kardioprotekcii pri jeksperimental’noj uremii. Nefrologija 2006; 10(1): 56-61]
(check this in PDF content)
17
Okoshi K, Ribeiro H, Okoshi M et al. Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy. Jpn Heart J 2004; 45(4): 647-656
(check this in PDF content)
18
Løhr M, Jensen A, Eriksen L. et al. Age and metabolic risk factors associated with oxidatively damaged DNA in human peripheral blood mononuclear cells. Oncotarget 2015; 20(6-5): 2641-2653
(check this in PDF content)
19
Арутюнов АГ, Драгунов ДО, Арутюнов ГП и др. Влияние основных факторов риска у пациентов на прогноз при декомпенсации сердечной недостаточности. Кардиология
(check this in PDF content)
20
4; 54(12): 37-43 [Arutjunov AG, Dragunov DO, Arutjunov GP i dr. Vlijanie osnovnyh faktorov riska u pacientov na prognoz pri dekompensacii serdechnoj nedostatochnosti. Kardiologija 2014; 54(12): 37-43] 20. Antelmi I, de Paula RS, Shinzato AR et al. Influence of age, gender, body mass index, and functional capacity on heart rate variability in a cohort of subjects without heart disease. Am J Cardiol 2004; 93: 381–385
(check this in PDF content)
21
Барабанова ВВ, Береснева ОН. Является ли паратиреоидный гормон основным повреждающим фактором сосудов печени при экспериментальной почечной недостаточности. Нефрология 1998; 2(1): 99-104 [Barabanova VV, Beresneva ON. Javljaetsja li paratireoidnyj gormon osnovnym povrezhdajushhim faktorom sosudov pecheni pri jeksperimental’noj pochechnoj nedostatochnosti. Nefrologija 1998; 2(1): 99-104]
(check this in PDF content)
22
Барабанова ТА, Пенчул НА. Миокард, паратиреоидный гормон и хроническая почечная недостаточность. Нефрология 1998; 2: 88-94 [Barabanova TA, Penchul NA. Miokard, paratireoidnyj gormon i hronicheskaja pochechnaja nedostatochnost’. Nefrologija 1998; 2: 88-94]
(check this in PDF content)
23
Amann K, Ritz E. Cardiac structure and function in renal disease. Curr Opin Nephrol Hypertens 1996; 5:102-106
(check this in PDF content)
24
Kim G, Won Oh K, Jang E et al. Relationship between Vitamin D, Parathyroid Hormone, and Bone Mineral Density in Elderly Koreans. J Korean Med Sci 2012; 27(6): 636–643
(check this in PDF content)
25
Dawson-Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713–716
(check this in PDF content)
26
Bischoff-Ferrari HA, Giovannucci E, Willett WC et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84:18–28
(check this in PDF content)
27
Kovesdy CP, Bleyer AJ, Molnar MZ et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013; 159(4):233-242
(check this in PDF content)
28
Mall G, Rambausek M, Neumeister A et al. Interstitial fibrosis in experimental uremia – implications for cardiac compliance. Kidney Int 1988; 33: 804–811
(check this in PDF content)
29
Добронравов ВА, Богданова ЕО, Семенова НЮ и др. Почечная экспрессия белка αKlotho, фактор роста фибробластов 23 и паратиреоидный гормон при экспериментальном моделировании ранних стадий хронического повреждения почек. Нефрология 2014; 18(2): 72-78 [Dobronravov VA, Bogdanova EO, Semenova NJu i dr. Pochechnaja jekspressija belka Klotho, faktor rosta fibroblastov 23 i paratireoidnyj gormon pri jeksperimental’nom modelirovanii rannih stadij hronicheskogo povrezhdenija pochek. Nefrologija 2014; 18(2): 72-78]
(check this in PDF content)
30
Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45–51
(check this in PDF content)
31
Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309:1829–1833
(check this in PDF content)
32
Rambausek M, Ritz E, Mall G et al. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985; 28: 775–782
(check this in PDF content)
33
Иванова ГТ, Кучер АГ, Береснева ОН и др. Оценка в эксперименте нефропротективного и кардиопротективного эффектов длительного применения малобелковой диеты, включающей кетостерил. Нефрология 2011; 15(4): 70-74 [Ivanova GT, Kucher AG, Beresneva ON i dr. Ocenka v jeksperimente nefroprotektivnogo i kardioprotektivnogo jeffektov dlitel’nogo primenenija malobelkovoj diety, vkljuchajushhej ketosteril. Nefrologija 2011; 15(4): 70-74]
(check this in PDF content)
34
Карабаева АЖ, Парастаева ММ, Береснева ОН и др. Влияние спиронолактона на течение экспериментальной хронической почечной недостаточности и гипертрофию миокарда у крыс Wistar. Нефрология 2008; 12(1): 64-68 [Karabaeva AZh, Parastaeva MM, Beresneva ON i dr. Vlijanie spironolaktona na techenie jeksperimental’noj hronicheskoj pochechnoj nedostatochnosti i gipertrofiju miokarda u krys Wistar. Nefrologija 2008; 12(1): 64-68]
(check this in PDF content)
35
Amann K, Neususs R, Ritz E et al. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995; 8(4): 409-417
(check this in PDF content)
36
Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 2003; 92: 1079–1088
(check this in PDF content)
37
Bongartz LG, Braam B, Gaillard CA et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012; 303(9): F1253-1263
(check this in PDF content)
38
Mall G, Rambausek M, Neumeister A et al. Myocardial interstitial fibrosis in experimental uremia – implications for cardiac compliance. Kidney Int 1988; 33: 804–811
(check this in PDF content)
39
Maruyama Y. Aging and arterial-cardiac interactions in the elderly. Int J Cardiol 2012; 155(1): 14-19
(check this in PDF content)
40
Tyralla K, Adamczak M, Benz K et al. High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy. PLoS One 2011; 6(1): e15287
(check this in PDF content)
41
Береснева ОН, Парастаева ММ, Иванова ГТ и др. Изменения сердечно-сосудистой системы у крыс, сопряженные с высоким потреблением хлорида натрия. Артериальная гипертензия 2015, 20(5): 384-390 [Beresneva ON, Parastaeva MM, Ivanova GT i dr. Izmenenija serdechno-sosudistoj sistemy u krys, soprjazhennye s vysokim potrebleniem hlorida natrija. Arterial’naja gipertenzija 2015, 20(5): 384-390]
(check this in PDF content)
42
Opie LH. Mechanisms of cardiac contraction and relaxation. In: Braunwalds heart disease: a textbook of cardiovascular medicine. Ed. D.Zipes, P. Libby, R.O. Bonow. Pensylvania: Elsevier Saunders 2005: 457-490
(check this in PDF content)
43
Xiang W, Kong J, Chen S, Li Y. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the system and cardiac rennin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: 125-132
(check this in PDF content)
44
Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: Cardiorenal effects and elderly cohort. The Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214-2220 Работа поддержана грантом Первого Санкт-
(check this in PDF content)